Evidence map›Paper›PMID 37798358›Full record

ReviewNature protocols2023

An expanded CRISPR-Cas9-assisted recombineering toolkit for engineering genetically intractable Pseudomonas aeruginosa isolates.

Debbie Pankratz, Nicolas Oswaldo Gomez, Agnes Nielsen, Ayten Mustafayeva, Melisa Gür, Fabián Arce-Rodriguez, Pablo Ivan Nikel, Susanne Häussler, Alejandro Arce-Rodriguez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. CRISPR-Cas9 applications in T cells and adoptive T cell therapies.Cellular & molecular biology letters · 2024
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Debbie Pankratz *Department of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID 0000-0002-1289-8175
Nicolas Oswaldo Gomez *Department of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID 0000-0001-5723-886X
Agnes NielsenDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Ayten MustafayevaInstitute of Microbiology, Technische Universität Braunschweig, Braunschweig, Germany.
Melisa GürInstitute for Molecular Bacteriology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.ORCID 0000-0001-6310-7612
Fabián Arce-RodriguezDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Pablo Ivan NikelThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-9313-7481
Susanne HäusslerDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany. susanne.haeussler@helmholtz-hzi.de.ORCID 0000-0001-6141-9102
Alejandro Arce-RodriguezDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany. alejandro.arce-rodriguez@tu-braunschweig.de.ORCID 0000-0002-2486-401X
Helmholtz Centre for Infection Research · DECopenhagen University Hospital · DKNovo Nordisk Foundation · DKTechnische Universität Braunschweig · DE

Funding

Det Frie Forskningsråd (Danish Council for Independent Research) 8021-00039BDeutsche Forschungsgemeinschaft (German Research Foundation) SPP 1879EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 814418Niedersächsische Ministerium für Wissenschaft und Kultur (Lower Saxony Ministry of Science and Culture) ZN3428Novo Nordisk Fonden (Novo Nordisk Foundation) NNF18OC0033946Novo Nordisk Fonden (Novo Nordisk Foundation) NNF18OC0034818Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20CC0035580Novo Nordisk Fonden (Novo Nordisk Foundation) NNF21OC0067996
6 · The paper itself

Abstract

Much of our current understanding of microbiology is based on the application of genetic engineering procedures. Since their inception (more than 30 years ago), methods based largely on allelic exchange and two-step selection processes have become a cornerstone of contemporary bacterial genetics. While these tools are established for adapted laboratory strains, they have limited applicability in clinical or environmental isolates displaying a large and unknown genetic repertoire that are recalcitrant to genetic modifications. Hence, new tools allowing genetic engineering of intractable bacteria must be developed to gain a comprehensive understanding of them in the context of their biological niche. Herein, we present a method for precise, efficient and rapid engineering of the opportunistic pathogen Pseudomonas aeruginosa. This procedure relies on recombination of short single-stranded DNA facilitated by targeted double-strand DNA breaks mediated by a synthetic Cas9 coupled with the efficient Ssr recombinase. Possible applications include introducing single-nucleotide polymorphisms, short or long deletions, and short DNA insertions using synthetic single-stranded DNA templates, drastically reducing the need of PCR and cloning steps. Our toolkit is encoded on two plasmids, harboring an array of different antibiotic resistance cassettes; hence, this approach can be successfully applied to isolates displaying natural antibiotic resistances. Overall, this toolkit substantially reduces the time required to introduce a range of genetic manipulations to a minimum of five experimental days, and enables a variety of research and biotechnological applications in both laboratory strains and difficult-to-manipulate P. aeruginosa isolates.

Indexed as

CRISPR-Cas SystemsPseudomonas aeruginosaDNA, Single-StrandedGene EditingGenetic EngineeringDNA, Single-Stranded

Identifiers

PMID37798358
OpenAlexW4387375317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.